Literature DB >> 9166955

Neuroborreliosis: central nervous system involvement.

J J Halperin1.   

Abstract

Despite rapid dissemination of Borrelia burgdorferi throughout the body following initial inoculation, the clinical manifestations of this illness tend to involve specific organ systems preferentially. The nervous system, in particular, is frequently affected; involvement usually follows one of several distinct patterns. Most commonly, patients develop a lymphocytic meningitis, radiculoneuritis or cranial neuropathy, occurring singly or in combination. Patients with radicular involvement often have a myelopathic component as well. At the other extreme, rare patients will develop focal inflammation of the central nervous system, an encephalomyelitis, that appears to involve white matter more often than grey. More commonly, patients may develop cognitive and memory impairment-a mild encephalopathy. In some patients this may represent a subtle form of encephalomyelitis, while in others it is probably a "toxic-metabolic" effect of systemic infection. Disease variability among patients probably is the result of multiple factors, including bacterial strain differences in virulence and organotropism, inoculum size, host immunity, and simultaneous co-infection with other tick-borne organisms. Accurate diagnosis remains somewhat problematic. The cerebrospinal fluid is almost always abnormal in the presence of active CNS infection. Intrathecal production of specific antibody can be demonstrated in over 90% of patients with meningitis or frank inflammatory encephalomyelitis; in patients with a milder encephalopathy this is less consistently observed. In most instances, diagnosis relies on a combination of demonstration of a specific immune response, and clinical judgment. In patients in whom the diagnosis is secure, appropriate antimicrobial therapy is highly effective in the vast majority of cases, although if there has been significant structural damage to the CNS, some residua may remain.

Entities:  

Mesh:

Year:  1997        PMID: 9166955     DOI: 10.1055/s-2008-1040908

Source DB:  PubMed          Journal:  Semin Neurol        ISSN: 0271-8235            Impact factor:   3.420


  7 in total

1.  The MEK/ERK pathway is the primary conduit for Borrelia burgdorferi-induced inflammation and P53-mediated apoptosis in oligodendrocytes.

Authors:  Geetha Parthasarathy; Mario T Philipp
Journal:  Apoptosis       Date:  2014-01       Impact factor: 4.677

2.  Cerebrospinal fluid-infiltrating CD4+ T cells recognize Borrelia burgdorferi lysine-enriched protein domains and central nervous system autoantigens in early lyme encephalitis.

Authors:  Jan D Lünemann; Harald Gelderblom; Mireia Sospedra; Jacqueline A Quandt; Clemencia Pinilla; Adriana Marques; Roland Martin
Journal:  Infect Immun       Date:  2006-10-23       Impact factor: 3.441

3.  Cranial neuropathy and severe pain due to early disseminated Borrelia burgdorferi infection.

Authors:  Derek Ebner; Kelsey Smith; Daniel DeSimone; Muhammad Rizwan Sohail
Journal:  BMJ Case Rep       Date:  2018-01-23

Review 4.  Molecular typing of Borrelia burgdorferi sensu lato: taxonomic, epidemiological, and clinical implications.

Authors:  G Wang; A P van Dam; I Schwartz; J Dankert
Journal:  Clin Microbiol Rev       Date:  1999-10       Impact factor: 26.132

5.  A possible role for inflammation in mediating apoptosis of oligodendrocytes as induced by the Lyme disease spirochete Borrelia burgdorferi.

Authors:  Geeta Ramesh; Shemi Benge; Bapi Pahar; Mario T Philipp
Journal:  J Neuroinflammation       Date:  2012-04-23       Impact factor: 8.322

6.  Chorea as a symptom of neuroborreliosis: a case study.

Authors:  I Piccolo; G Thiella; R Sterzi; N Colombo; C A Defanti
Journal:  Ital J Neurol Sci       Date:  1998-08

7.  Inflammatory mediator release from primary rhesus microglia in response to Borrelia burgdorferi results from the activation of several receptors and pathways.

Authors:  Geetha Parthasarathy; Mario T Philipp
Journal:  J Neuroinflammation       Date:  2015-03-28       Impact factor: 8.322

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.